| abstract |
(57) [Summary]nPROBLEM TO BE SOLVED: To use a cysteine derivative for the manufacture of a medicament intended for treating a disease resulting from the formation of a heterotrimeric G protein. These diseases include in particular those associated with the following biological functions or disorders: olfactory, taste, light perception, neurotransmission, neurodegeneration, endocrine and exocrine gland function, autocrine and paracrine regulation, arterial pressure, embryo There are diseases associated with formation, benign cell proliferation, oncogenesis, viral infection, immune function, diabetes, obesity and benign and malignant proliferative diseases. Among the above cysteine derivatives are in particular the following compounds: (i) bis-1,1 '-[7- (2-amino-1-oxo-3-thiopropyl) -8- (cyclohexylmethyl) -2- ( 2-methoxyphenyl) -5,6,7,8-tetrahydroimidazo [1,2a] pyrazine disulfide (I) and (ii) bis-1,1'-7- (2-amino-1-oxo-3 -Thiopropyl)-(2- (1-naphthyl) -8- (2-methylpropyl) -5,6,7,8-tetrahydroimidazo [1,2a] pyrazin-7-yl) disulfide (II). |